II. Indications
III. Contraindications
- Mechanical Bowel Obstruction
- Children (esp. age <6 years)
IV. Mechanism
V. Dosing
- Take 290 mcg orally daily at least 30 minutes before first meal of the day
- May be given by Nasogastric Tube via opened capsule and mixed with 30 ml water
VI. Efficacy
- May improve stool frequency, consistency and straining in Irritable Bowel Syndrome
- Marginal efficacy (NNT 5-8) for decreased Abdominal Pain
VII. Adverse Effects
- Abdominal Pain
- Abdominal Distention
- Flatulence
-
Diarrhea
- Hold Linaclotide for severe Diarrhea
VIII. Safety
- Pregnancy Category C
- Unknown safety in Lactation
IX. Drug Interactions
- No known Drug Interactions
X. Resources
XI. References
- (2012) Prescr Lett 19(12): 68-9
- (2021) Irritable Bowel Syndrome Drug Comparison, Presc Lett, #370305
- (2020) Med Lett Drugs Ther 62(1594): 41-58
Images: Related links to external sites (from Bing)
Related Studies
| linzess (on 1/14/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| LINZESS 145 MCG CAPSULE | $15.71 each | |
| LINZESS 290 MCG CAPSULE | $15.69 each | |
| LINZESS 72 MCG CAPSULE | $15.70 each | |
Ontology: linaclotide (C2000261)
| Definition (NCI) | A synthetic, fourteen amino acid peptide and agonist of intestinal guanylate cyclase type C (GC-C), which is structurally related to the guanylin peptide family, with secretagogue, analgesic and laxative activities. Upon oral administration, linaclotide binds to and activates GC-C receptors located on the luminal surface of the intestinal epithelium. This increases the concentration of intracellular cyclic guanosine monophosphate (cGMP), which is derived from guanosine triphosphate (GTP). cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) and stimulates the secretion of chloride and bicarbonate into the intestinal lumen. This promotes sodium excretion into the lumen and results in increased intestinal fluid secretion. This ultimately accelerates GI transit of intestinal contents, improves bowel movement and relieves constipation. Increased extracellular cGMP levels may also exert an antinociceptive effect, through an as of yet not fully elucidated mechanism, that may involve modulation of nociceptors found on colonic afferent pain fibers. Linaclotide is minimally absorbed from the GI tract. |
| Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
| MSH | C523483 |
| SnomedCT | 703126002, 703686003 |
| English | linaclotide, [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide, L-Tyrosine, L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L- asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-, cyclic (1->6), (2->10), (5->13)-tris(disulfide), LINACLOTIDE, linaclotide (medication), anti-constipation linaclotide, Linaclotide, Linaclotide (product), Linaclotide (substance) |
